1.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.61
Aprire:
$1.61
Volume 24 ore:
2.04M
Relative Volume:
1.10
Capitalizzazione di mercato:
$157.65M
Reddito:
-
Utile/perdita netta:
$-37.34M
Rapporto P/E:
-1.1544
EPS:
-1.36
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
-0.63%
1M Prestazione:
+0.64%
6M Prestazione:
+44.04%
1 anno Prestazione:
+8.28%
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Nome
Sellas Life Sciences Group Inc
Settore
Industria
Telefono
(646) 200-5278
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Confronta SLS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SLS
Sellas Life Sciences Group Inc
|
1.57 | 157.65M | 0 | -37.34M | -36.91M | -1.36 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
446.15 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
517.60 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
304.00 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.70B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
BNTX
Biontech Se Adr
|
108.97 | 27.19B | 2.97B | -812.83M | -1.24B | -3.3962 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-07-21 | Iniziato | Cantor Fitzgerald | Overweight |
2018-11-01 | Iniziato | Oppenheimer | Outperform |
2018-04-02 | Iniziato | H.C. Wainwright | Buy |
2018-03-19 | Aggiornamento | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
SELLAS Life Sciences Expands Scientific Advisory Board with - GlobeNewswire
SELLAS Life Sciences Expands Scientific Advisory Board - citybiz
SELLAS adds oncology experts to advisory board - Investing.com
SELLAS adds oncology experts to advisory board By Investing.com - Investing.com Nigeria
Leading Oncology Experts Join SELLAS Advisory Board as Critical AML Trial Results Near - Stock Titan
Northern Trust Corp Acquires 33,878 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Lif - GuruFocus
SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com South Africa
SELLAS reports potential colorectal cancer therapy progress - Investing.com India
Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
SELLAS Life Sciences (SLS) Highlights Promising Results for SLS0 - GuruFocus
Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire
Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan
Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail
Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences Group - TipRanks
Sellas Life Sciences Reports Improved Financial Position - TipRanks
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times
SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan
Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance
SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa
Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com
SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus
SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire
Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan
SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus
SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX
Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX
Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News
SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com
SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com
SELLAS reports promising AML treatment in preclinical study - Investing.com
SELLAS Life Sciences (SLS) Reports Promising Preclinical Results for SLS009 in Leukemia | SLS Stock News - GuruFocus
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - The Manila Times
Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan
SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com
The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News
BILI Shares Experience Surge in Value - knoxdaily.com
SLSSellas Life Sciences Group Inc Latest Stock News & Market Updates - Stock Titan
Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World
Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sellas Life Sciences Group Inc Azioni (SLS) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):